A new era of proactive melanoma therapy: hit hard, hit early.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [European journal of nuclear medicine and molecular imaging · 2022
   Article
2. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.Journal of surgical oncology · 2019
   Article
3. Sentinel bruising as a presentation of metastatic melanoma.BMJ case reports · 2019
   Article

Corrections and comments

• Comment on
  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.2017
• Comment on
  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.2017
• Comment on
  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as